TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Brief Summary: To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate \[complete response (CR) + partial response (PR)\], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
B: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
C: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
D: Arm Label: Lenvatinib + Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib + Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib + Pembrolizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma (MPM) With or Without Hemithoracic Radiotherapy. A Randomized Multicenter Phase II Trial
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This randomized phase II trial is studying how well giving pemetrexed disodium together with cisplatin followed by surgery with or without radiation therapy works in treating patients with malignant pleural mesothelioma.


Options:
A: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pemetrexed disodium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab; Assigned to Arm(s): 2
C: Arm Label: single arm of Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm of Tremelimumab
D: Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately
Brief Summary: The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A
C: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately
Brief Summary: The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.


Options:
A: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
C: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately
Brief Summary: The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Bivalent OPV 2 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 2 week interval | Arm Label: Bivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 4 week interval | Arm Label: Monovalent OPV 2week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 2 week interval | Arm Label: Monovalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 4 week interval | Arm Label: Trivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 2 week interval; Assigned to Arm(s): Bivalent OPV 2 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 4 week interval; Assigned to Arm(s): Bivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 2 week interval; Assigned to Arm(s): Monovalent OPV 2week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 4 week interval; Assigned to Arm(s): Monovalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Trivalent OPV 4 week interval; Assigned to Arm(s): Trivalent OPV 4 week interval
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).


Options:
A: Arm Label: stimulant medication; Type: EXPERIMENTAL; Interventions: Drug: lisdexamfetamine | Arm Label: placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: lisdexamfetamine | Intervention Type: DRUG; Name: lisdexamfetamine; Assigned to Arm(s): placebo pill, stimulant medication
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: NRp104 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: NRp104; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: LDX Treatment; Type: EXPERIMENTAL; Interventions: Drug: LDX Treatment | Intervention Type: DRUG; Name: LDX Treatment; Assigned to Arm(s): LDX Treatment
D: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
B: Arm Label: Liberal Group; Type: EXPERIMENTAL; Interventions: Other: Haemoglobin 9.5 g/dL | Arm Label: Restrictive group; Type: ACTIVE_COMPARATOR; Interventions: Other: Haemoglobine 7.5g/dL | Intervention Type: OTHER; Name: Haemoglobin 9.5 g/dL; Assigned to Arm(s): Liberal Group | Intervention Type: OTHER; Name: Haemoglobine 7.5g/dL; Assigned to Arm(s): Restrictive group
C: Arm Label: Liberal RBC Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Other: Liberal Red Blood Cell Transfusion Strategy | Arm Label: Restrictive RBC Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Red Blood Cell Transfusion Strategy | Intervention Type: OTHER; Name: Liberal Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Liberal RBC Transfusion Strategy | Intervention Type: OTHER; Name: Restrictive Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Restrictive RBC Transfusion Strategy
D: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
B: Arm Label: VIT-45; Type: EXPERIMENTAL; Interventions: Drug: VIT-45 | Arm Label: Oral iron tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral iron tablets | Intervention Type: DRUG; Name: Oral iron tablets; Assigned to Arm(s): Oral iron tablets | Intervention Type: DRUG; Name: VIT-45; Assigned to Arm(s): VIT-45
C: Arm Label: Iron isomaltoside 1000 (Monofer®); Type: EXPERIMENTAL; Interventions: Drug: Iron isomaltoside 1000 | Arm Label: Standard medical Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard medical Care | Intervention Type: DRUG; Name: Iron isomaltoside 1000; Assigned to Arm(s): Iron isomaltoside 1000 (Monofer®) | Intervention Type: OTHER; Name: Standard medical Care; Assigned to Arm(s): Standard medical Care
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Liberal transfusion strategy | Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Behavioral: Restrictive transfusion strategy | Intervention Type: BEHAVIORAL; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal | Intervention Type: BEHAVIORAL; Name: Restrictive transfusion strategy; Assigned to Arm(s): Restrictive
B: Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Intervention Type: BIOLOGICAL; Name: Administration of Red Cell; Assigned to Arm(s): Liberal, Restrictive
C: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
D: Arm Label: RBCT based on rSO2 value; Type: EXPERIMENTAL; Interventions: Procedure: Red blood cells transfusion | Arm Label: RBCT based on hemoglobin level value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red blood cells transfusion | Intervention Type: PROCEDURE; Name: Red blood cells transfusion; Assigned to Arm(s): RBCT based on hemoglobin level value, RBCT based on rSO2 value

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Restrictive RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Restrictive RBC Transfusion | Arm Label: Liberal RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Liberal RBC Transfusion | Intervention Type: BIOLOGICAL; Name: Restrictive RBC Transfusion; Assigned to Arm(s): Restrictive RBC Transfusion Group | Intervention Type: BIOLOGICAL; Name: Liberal RBC Transfusion; Assigned to Arm(s): Liberal RBC Transfusion Group
B: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
C: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: C